UPDATE: RBC Capital Issues Positive Comments on Akebia Therapeutics (AKBA), Believes Shares Could Trade Up $5 to $8 on Data
Tweet Send to a Friend
(Updated - May 5, 2020 9:25 AM EDT)(expanding comment)RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Akebia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
